Analysts Lift Outlook on Johnson Controls International
Leading market analysts are turning more positive on several well-known names, and Johnson Controls International plc (NYSE: JCI) is among the standouts. The recent shifts in ratings point to growing confidence in the company’s execution and place in the market.
Tuesday’s Notable Upgrades
The week opened with a cluster of upgrades for major companies across sectors. Here’s a clear look at what changed—and what it might signal.
Oracle Corporation Sees a Brighter Call
JMP Securities analyst Patrick Walravens moved Oracle Corporation (NYSE: ORCL) from Market Perform to Market Outperform and set a new price target of $175. Even with a modest 1.4% dip that left shares at $139.89 recently, the rating change points to a constructive view of Oracle’s path ahead.
Johnson Controls International Gains Momentum
B of A Securities analyst Andrew Obin upgraded Johnson Controls International plc (NYSE: JCI) from Neutral to Buy and raised the price target from $76 to $80. The stock advanced 1.1% to close at $68.60, a move that suggests investors took the upgrade as a sign of improving prospects.
Equity Residential Moves Up the Ranks
Deutsche Bank’s Derek Johnston lifted Equity Residential (NYSE: EQR) from Hold to Buy and increased the price target from $62 to $83. Shares rose 1% to finish at $75.10, a gain that aligns with the firmer stance on the company’s resilience in today’s market.
Delek US Holdings Draws a Reassessment
JP Morgan analyst John Royall shifted Delek US Holdings, Inc. (NYSE: DK) from Underweight to Neutral and nudged the price target from $23 to $26. The stock still slipped 3.9% to $18.75, a reminder that upgrades can coincide with near-term pressure as the market works through a transition.
Relay Therapeutics Jumps on Upgrade
Jefferies analyst Akash Tewari upgraded Relay Therapeutics, Inc. (NASDAQ: RLAY) from Hold to Buy and raised the price target from $10.6 to $16. Shares surged 52.4% to $9.51, reflecting a sharp swing in sentiment and fresh optimism among investors.
Reading the Signal on JCI
For JCI, the move to Buy is a clear vote of confidence. It suggests analysts see better alignment between the company’s strategy and its outlook, with the higher price target reinforcing that view. If you’re tracking JCI, it’s worth watching how industry trends unfold and how subsequent analyst notes build—or temper—this momentum. The initial 1.1% move after the call is just that: an initial read from the market.
Frequently Asked Questions
What does the new Buy rating for Johnson Controls International imply?
It reflects increased confidence in Johnson Controls’ performance and profitability. The analyst also raised the price target from $76 to $80, and shares closed up 1.1% at $68.60 following the change.
What exactly changed for Oracle, and how did the stock trade?
Oracle was upgraded by JMP Securities from Market Perform to Market Outperform with a $175 price target. Despite the stronger rating, the shares dipped 1.4% to $139.89 recently.
Do analyst upgrades always push stocks higher?
Not always. Upgrades can attract interest and support prices over time, but near-term moves vary. In this roundup, some stocks rose on the news while others, like Delek US Holdings, fell even after an upgrade.
Which other companies were upgraded alongside JCI?
Equity Residential was raised from Hold to Buy with a higher target of $83 (from $62), Delek US Holdings moved from Underweight to Neutral with a target increase to $26 (from $23), and Relay Therapeutics was lifted from Hold to Buy with a target of $16 (from $10.6).
What should I watch next for JCI?
Keep an eye on industry trends, future analyst commentary, and signs that the company is executing on its strategy. The recent upgrade signals a reassessment of JCI’s business health, but the follow-through will matter.
